April 01, 2013 09:15 ET
TORONTO, ONTARIO--(Marketwire - April 1, 2013) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) today announced that the Company received approval from shareholders to approve all resolutions that were put forth at its Annual Meeting of Shareholders held on March 29, 2013 in Toronto (the "Meeting") and as disclosed in its management information circular filed on SEDAR in connection to the Meeting.
Two additional resolutions were put forth before the Meeting and received approval of 100% of the votes cast by shareholders present. The first resolution allows the board of directors of the Company, at its discretion, to delist the Company's common shares from the Canadian National Stock Exchange. The second resolution authorizes the board of directors, at its discretion, to seek an application to list the Company's common shares on the Toronto Stock Exchange or TSX Venture Exchange.
About Arch Biopartners
Arch Biopartners is a portfolio based technology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
The Company's website address is: www.archbiopartners.com.
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.
Arch Biopartners Inc.Richard MuruveCEO(647) 428 email@example.com
See all RSS Newsfeeds